David A. Siegel Tarsus Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 256,400 shares of TARS stock, worth $14.1 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
256,400
Previous 307,600
16.64%
Holding current value
$14.1 Million
Previous $8.36 Million
0.86%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding TARS
# of Institutions
170Shares Held
43.3MCall Options Held
484KPut Options Held
4.1K-
Rtw Investments, LP New York, NY3.41MShares$188 Million1.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$180 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$134 Million2.89% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$124 Million6.32% of portfolio
-
Morgan Stanley New York, NY2.21MShares$121 Million0.01% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.47B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...